AVTR · Avantor, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $473.7M | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 14.5% | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted EPS non-GAAP | $0.21 | Q2 2026 | — |
| Adjusted net income non-GAAP | $143.3M | Q2 2026 | — |
| Adjusted Operating Income non-GAAP | $415.7M | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted Operating Income margin non-GAAP | 12.7% | Six months ended June 30, 2026 | — |
|
|
|||
| Bioscience & Medtech Products Adjusted Operating Income non-GAAP | $117.6M | Q2 2026 | — |
| Bioscience & Medtech Products Adjusted Operating Income margin non-GAAP | 24.9% | Six months ended June 30, 2026 | — |
| Bioscience & Medtech Products organic sales decline non-GAAP | 5.6% | Q2 2026 | — |
| Free cash flow non-GAAP | $168M | Six months ended June 30, 2026 | — |
|
|
|||
| Organic net sales decline non-GAAP | 0.4% | Q2 2026 | — |
| VWR Distribution & Services Adjusted Operating Income non-GAAP | $126.4M | Q2 2026 | — |
| VWR Distribution & Services Adjusted Operating Income margin non-GAAP | 9.7% | Six months ended June 30, 2026 | — |
| VWR Distribution & Services organic sales increase non-GAAP | 1.7% | Q2 2026 | — |
| Adjusted net leverage non-GAAP | 3.2 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTR
this stock
Avantor, Inc.
|
$9.88B | +26.5% | -3.4% | — | 7.6% |
|
ISRG
Intuitive Surgical Inc
|
$131.36B | -34.6% | +20.5% | 42.7 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$51.65B | — | +8.2% | — | 3.4% |
|
MDLN
Medline Inc.
|
$46.36B | -17.7% | +11.5% | — | 2.8% |
|
ALC
Alcon Inc
|
$35.63B | -7.8% | +10.5% | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTR | +3.9% | +0.8% | +70.2% | +5.2% | +26.5% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +4.3% | -4.2% | +57.8% | +2.7% | +14.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.